An ual , epott Year ended 31 March 2022 Yorkshire Cancer. Research
CONTENTS Welcome: Introduction to our charity Chief Executlve's Welcome 03 Chair's Report 05 Trustees and Strategic Report Our Team- Board of Trustees 07 Our Purpose Our Vision and Values 09 Strategic Aims Our Key Achievement5 - Our research in numbers Working to prevent cancer Diagnosing cancer early Improving cancer treatments - Other charity achievement5 io 12 16 20 24 Flnancial Review - General Financial Review and Principle Sources of Funding 28 Principal Risks and Uncertainties Independent Auditors Report 36 Con501idated Financlal Statements Financial Statements 40 Balance Sheet 42 Notes to financial statements
Yorkshire's independent cancercharity. Yorkshire 15 one of the region5 hardest hit by cancer. Yorkshire Cancer Research exists to change this. More people are diagnosed with this lrfe-changing disease in our region than In most other parts of England. More people Suffer the tragedy of losing a loved one. Yorkshire Cancer Research exists to reduce these health inequalities and save lives. By bringing cancer research to Yorkshire. we shine a spotlight on the region s biggest cancer problems and attract the very best cancer experts from around the country and the world. Together, we are finding new and better ways to help save more lives - in your city, your town and your local community. Yorkshire Cancer. Research For every family who's lost a loved one For the people who still don't know they're at risk For the cures we haven't found yet For world-class treatment no matter who you are, or where you live For North, South. East and West Yorkshire For this generation For the next generation For more life without canor
? CHIEF EXECUTIVE'S I1111 WELCOME Hello, l am delightedto lntru(xeYLYkthweCartsrRwr(hSknM Rwrt fuThYrai5ersand kn31 Comm[1tygrXpS-itltal of these PEcpraY tKteaiYetocarry outourvitd rde TharElL very Lstand L&treatmentsforc3nw. Thsyww aWar(l£11.7mlolUTrd reprent&J.'LÉvdliwvJ rnaYbe a rpfry9etMJt itswth ojr ttw1tythtrenrO tOard5s1rI92S.erwriro tw kEalthrUrtie5arerdlKedwmIStardSofCe iffycv&l. ThisyearwewroteanoFen er to th Health Secretary. SajKI (rj UpY hintostaTrJ tyhlscommttmerrtto pLdea10nalmdforuCaIKerr(Ipr£DTh. We ntributed to Drjed Khan08Vs'MryJg)¥NJ(4ete.1rtt nati(rral rnedk4 attentmwe aLSO pwbopoted in TheCBrr£rVoiTr'urgiryJ emMentto this. benefit- an athantajefelt byEwewne. RearchfurKfro attr5 reSeC¥I reprents neaty8%oftheLIKs txrtcty3% M8c81 re5ChfU11J.eYPjttt0 oroe thig Thsye¥wear4 agaryttEby>stfurNJerofcar£er TesearthstttytyFknYork5hiTe- We thankSfOry(XITlnfWbthr#jWt atoJtoJrth*ttyaThJ u5aThJ save IntesinYorksFire. Serely. Dr. K2thryn Ott d yorkshirecunc4rreseor¢h.org.uk
CHAIR'S REPORT Welcome, l am priwleged tobwlccffie tottysfv AnNal Rew YorksFireCanw Research is an iepe1¥jentChartyth8t tro5avrt4 role ints Iwlthof oJrregiorL our rArtkA)k goes far beyorxlyorkshire. rairn tOgNe pa¥le inyorkslire atce55to the best and latest cancer treatrnentsfrom arouTrl the to plOr rwi iMat1)n5 Incaer cwe . whichthen goon to improve carw acr0551hegki Thisyearwe laUd a aryj imwrtwrt Irfient in Car exwcise rehal[tatI¢. Partn2rirKJ with Sheffield HalIam'sA(fvared Wele1 Re5earchCentre. pw)1ebthC3ncersrÈ beirvJ offered an iThYNidualwl prwamrne0fexerce. aTvJ nu1rtll gJPFQrt. New research ftom acro55the world indicates tW exerctse. in t)ju[tionwith tradittt) forn of caKer treatrnent 1gJrgery, chemotheraFY and radh)theraFwX can 5V4nifKanttyimpreCagjNlvaI rate5 a trartsform INe& We are exctted by this opFKJrtunty at•J aim to be * theforefrirt of exerose c¥)colwso that evewe with cancer inyoththtye Can1tfrOrn this. We k))k forward to sharing nes of otlEr gjch prL¥rame5 in the com1r9aT. Thereare I30.0 peopge in York5hirE FAArtripatinJ n reseCh fuThknJ by(yJdwtty. We FEve 54 active re5eaTch awards aTrY 756 researc1$. cantywJertsandcAncerthampiws across the CountryaW(xkIngon programmes funded tyyorkshwe CatKer Researckn hdpiTYJ tofind solution5toYorkslwre's blggest carKer Proble. are thathl to eworof these irKlwhlu for hdpng tochar¥Je Yorkshire's c[ sicry. forg¢xxJ. FolkY1rJ th2dL%ruptK caused bythe paThJemi l am pleaEed toreiMYtth3t cwr research programmes are runnirKJ at full capKity. Try5 sakl. we nMstwJaCkMkdgethatthetcl on people with canw has been greatandthe impart oftfrt paThJemKwill contiryje to be fert for years tocorne. make5 useven rTh)redetemiird to attrtthe supiKrt aTrY fuling to ilwestin n&v to help rEoplewfth aThJ efi9j that pare ae tofNe kjd healtlry Iwe5. Bestwthes. Graham BeNlle
Trustees Report Yorkshire Cancer Researcli 6 yorkshlrecanc¢fftseqrclLorg.uk
BOARD OF TRUSTEES EXECUTIVE TEAM Mr Graham 8erville BSC (Hons) (Chair) Dr Kathwh Scott Bso PhD Chief Executwe Mrs Sandra Dodson BA (Hon¥ (OepLtty Chair) Dr Yvette Oade Bsc (Honsl. MBChB. FRCPCH Mfs Juliet Glendinning BA (Hons). Dip Director of Bfand Relationships Mrs Joanne Mornin BA (Hons). ACA Difector of FInar and Corporate 5ervice5. Company Secretary (appointed 01 Jan 20211 Mrs Catherlne Rustomji LLB (Europe). LPC treslgne(114 Oci 20211 Mr Bobby Ndawula Bsc (Honsl, FCA Ms Liz Richards BA IHonsl. ACA hAs Rosemary Cook CBE. HonDLitL Msc, PGDip. RGN. FQNI.FRSA Dr Sart Gdffiths BSC. PhD Direct of Research and Servlces Mr Chris Slater MCIPS ITesMJned 02 Feb 3J22) Mrs Clare Field MA (Honsl Oxon Mrfimothywilliams LL8 IHons}. LLM Company SeCtsry {retiTed 31 Dec 20201 Or Paul Rice BA (Jolnt Hons). MSC. Pho, FBCS Mr Craig Bonnar MA Hons (Econ) Mr 5am Jenner BA (Honsl LLM TEP (appointed 14 2022) Mr Matt Johnson Bsc (Honsl (appointed 14 Jun 2022) Heathei Jackson MA {Hon51 Oxon (appointed l Oct 2022) Sir Alan Langlands FRSE Hon FMed5ci (appointed 20 Sept 20221 REGISTERED OFFICE SOUCITORS INVESTMENT MANAGERS Jacob Smith House 7 Grove Park Court Harrogate HGI 40P The Chanty engages the most Evelyn Partners appropriate Solicitots for the 45 Gresham 5t given circumstarKe arKI doe5 not London retain a dedicated practice AUDITORS EC2V 7BG REGISTEREO CHARI7 NUMBER 516898 (England and Wal&sl Quilter Cheviot Limited 4th Aoor. The Pinnacle 73 Kir¥J Street anchester RSM UK Audit LLP Central Souaie 29 Wellington 5tsEet Leeds LSI 40L REGISTEREO COMPANY NUMBER 1919823 M24NG BANKER5 Lloyd5 TS8 Bank PIC 617 Park Row Leeds L51 INX
Our purpose Yorkshire Cancer Research is dedicated to funding research so that you and those you love live longer, healthier lives. Our aim is for at least 2000 more people to survive cancer in Yorkshire every year. To do this. each year we fund £10 million of world-leading research to prevent, diagnose and treat cancer. llllll -4 .k iiiilw'r
Our Vision and Values How we help We fund cancer experts and world-leading researchers who pioneer early cancer diagnosis and discover new and better treatments for people with cancer. These life-giving medical breakthroughs lead to the very best chance of recovery for people in Yorkshire. Vision Mission Goal People in Yorkshire are less likely to get cancer arKI le55 likely to die from It than elsewhere in the country Taking actiorb today to have the biggest impact on cancer for people in Yorkshire 2000 fewer cancer deaths a year in Yorkshl Strategic Aims l. Practical. tanglble. research-led actlvlty 2. Taklng action to prevent cancer in Yorkshire 3. Yortshlre people get the earfle5t possible diagnosls 4. Flnd better treatments to improve Su1Val In Yothshire
Funding research that saves lives in Yorkshire Thanks to the generosity of supporter5. Yorkshire Cancer Research plays a vltal role in helping more people in Yorkshire get access to the very best cancer treatment. Through the programmes we fund. we help attract the best cancer experts to reduce health inequalities and increase standards of care acr055 our region. 1 £11.7 £11.7 millDn to fijnd Fwon*ring research and seNices to prevent. diagnose and cancer. million 130.000 130,000 people are able to take part in research studies fvnded by yoshire Cancer Research. Our charity remains the biggest funder of cancer research stuoy places in Yort<shire. gmng more people access to new and innovative people 756 756 researchers cancer experts and cancer champions acro the country are engaged in programme5 fundeyl by Yorkshire Cancer Research, bringing expertise and kncwledge to our region to change Yorkshire's cancerfs story for good. researchers ID york5hir8rancorresearch.oig.uk
Our ke achievemen r7 .r.s' li
Yorkshire Stop Smokin Study Yorkshlrn Cancar Research Working to prevent cancer Yorkshire Cancer Research funds research and services to prevent. diagnose and treat cancer. Through life-giving medical breakthroughs. we aim to give people the very best chance of recovery here in Yorkshire and beyond. 12 yorkshlrncancen¥sÉtYrtILoYg.uk
Our ke achievemen Genetic screening to find families at risk of cancer One in every 20 cancer5 in women are caused by genetic defect5 that are passed down through families and are potentially preventable. However. 97% of women with these genetic defects remain unidentified. If found through testing, women can take measures to prevent breast. bowel. womb and ovarian cancer developing. They can also get screened regularly so that if they do develop cancer they are diagnosed at the earliest Possible stage when more treatment options may be available. and survival is more likely. Yorksh1reCanr ReseaKh is fvr¥Jing a£3.1 rni#k trial. led by Profe550r Ranjti Manchanda at()Jeen Mary Unwersicyof L(don. Tr'FOTEcf trial will investigate the rfsks, benefits feasibilttyor Introdudng testingforall womerL Th(xJ5andsof parathgm for implementing men livirKJ inyorkshire will be offered tests tof genth testing in healthcare for wt rfthey are at hhjh riskof catKer aspartof ttN5 patient and population benefit. new cllnlcal trial. The firKIiw5 could tsar6form the way women, and their families, fiNI (Krt rf theywe at hKJh This approach can prevent riskofcanw, meaning ttrw a (hoiceKI can thousands more cancers ti tskesteps to 1xttancw. any current clinical strategy, sawng the lives of many Tr critically important and Professor Ranjit Manchanda Read more here * cUendY womenare manty Klentified as beirvJ a carrier of a high-riskgene afterttrw have LEen diagrK)d wtth a carKworafter d05e TeSati¥v been diagTh%ed.
Innovation in cancer screening Around 4 in 5 people will have HPV (human papillomavirus) at some point in their lives - it is a common virus spread through any sexual activity. It IS normally cleared by our immune system but in some cases will cause changes to the cells of the cervix (part of the female reproductive system). If left untreated these cells can develop into rvICal cancer. HPV causes almost all cases of cervical cancer but as there are no symptoms. HPV often goes unnoticed. Cervical screening, which tests for HPV. is only available up to the age of 64 $0 those aged 65 and over may not know they have the virus and are at risk of developing cancer. If HPV is detected. additional monitoring and screening can be put in place aimed at finding cell changes or cancerous cells ear5y. y¥[eca[£rResearth 15 fvnding a £l.S millwJn st. kd by (TrM3nd P¥ofessorJran Peto aithe LoTh)nSdThxlof & Tropkal Mediane. thatwlfcusts) tsweventw)n OfrVal carte¥ In ckn W[[. Mcfe than SOOOwomen in Hull aged ceMc4 screeThro wll be Irmted to partic1Ke Inthls researthstu(ty. Ttrky Mll beofferal an'at.j. urine te5ttlEtcandetert FPV. The siastrJdi rf at.e tests a effec1ewty to re[ canr i) thts ohlerwJe gr "MHPVIS detected thrwh the iuine tes¢ those with HPV will be able to receive fither tests CJareGIkn. LcdOn SctrKol of HwJier* & T¥oplcal 14 kSl1£canCerSearthOry.k
Our ke achievemen Leading the agenda on smoking cessation Yorkshire has the highest smoking rates in England and lung cancer causes around 3000 cancer deaths here each year, more than any other cancer. Helping people to Stop smoking is essential to reducing cancer rates across our region. The high rate of smoking in Yorkshire has a huge and detrimental impact on people's health and also on our local healthcare services. The overall cost of smoking to society in Yorkshire exceeds £1.6 billion each year. Every person who stops smoking tobacco immediately improves their own health and reduces their risk of developing cancer. Yorkshire Canr Research continue5to a leader everyhospital patiwtt inthe regicnloverthe aue in helping people to 5tCP 97Ing. Thsyw of12) whtssrrth5 11 offed hdp to 5toB 45 charity has fiJtNYed agrouThJ.teaknThJ stop911j tiawiedTobaccoTreatment Adviser5. funded ty programrne in partnership wtth gJJlhYorkstrMre YoTksFure CAncer Re5eafth. are wowding speoali5t and BasseaW Integrated CareSrrL.QUff' istr stw smokiro SUPPKrt topewe in hc6pitd.TrNs largest projett of its kiThY intheworkl arKY has tr i)chJdes ac£e55tofree nne TeplE£emerrt therapies Fotential tosave up to2000 fNes proMrt 4X INRn.givirythemthe best ofgKressfvlly htspital readrni5sn5ayear. reCLry srrKbrg IpJrtbryforW. atobacco addictionttstoften stsrts in chld "By treating toL7acco addict will save lives decrease inequalities in health and save the NHS money that can be rnnSted in new seniice%- Or Richardjenknns. Chief ExtiVe of Bamsley Fkrf)rtal NHS FJ[KI3yrU5t Read more here Is
Diagnose cancer early when it's easier to treat If cancer is found early, it is often easier to treat, so early diagnosis is vital in helping to save lives. Yorkshire Cancer Research funds services that help people understand cancer signs and symptoms. Programmes we fund also help increase participation in vital screening services that identify the very earliest signs that cancer may be developing. ,.Y.I 16 yorA5'lÉC0n£Èrr9seq1¢1L0ry.uk ,
Our ke achievemen Tackling Yorkshires biggest cancer killer More people die of lung cancer in our region than of any other type of cancer almost 3000 people a year. 14% of all cancers diagnosed in Yorkshire are lung cancer yet, tragically. it accounts for 22% of cancer deaths. Lung cancer is higher in Yorkshire than in England a5 a whole. One reason for the high rates of lung cancer deaths in Yorkshire 15 that people with lung cancer often do not experience or recognise symptoms until the cancer is advanced and treatment options are limited. Unlike breast, bowel and cervical cancer. there is no national screening programme for lung cancer- something our charity is helping to change. The rnulti.mil1lc FK)uNI Leeds Luro Health Check clinical trial was flrstlauhed kn ember 20 sincethistime. cwer701KI people hwe tjeen anned and rnorethan 230[e0e in t cityhwe been diagrKJsed with caw. In totsl. more than 13.(MJO scans have taken Thelrial ts orEof the lurgscreenirAJ tria15 0erbnIMlTrJ inthe world. tt ps rkit ontyhelrthl tosave the INesof nnyp0)E4e but it has also pr¢Ve vrtal ewderKe and test to the UK National Screening prtet guKlarKe required for a decisK)n tobe Con7mtiee to help detemu'ne how on a naticTrwide NHS kjrg een1rj Fwamme. The chalityha5recendyannound an addtbonal EQ5 a national lung cancer screening Tnllliontogive PEOFAe at high rEkoflurKJ the progmmme could be introduced. opportuntyto receNe a further fthw.Lpxan fc earfy sigr6 cAcarKer. The new fvnthng will yield further idence to shape lung cancer screernng in the UK w.le saving Ihe InnotiOnS led by thi.s tnal into the NHS England Targeted Piofewr MatthLw Calli5ter. Le&J5Teachi Hospitds 17
detection o Around six in 10 kidney cancers are only diagnosed during test5 for another condition or reason. In many cases, there are no obvious symptoms of kidney cancer at first. This means over a third of patients are diagnosed at a late stage when the cancer is more difficult to treat. Around two in three patient5 with kidney cancer live for five years after diagn05iS. Sin2018, Yorkshire CarKer Research has furKled of k¥JrWCa. Led ty Profe55orGrantStewart at an extensNe lurKJ Canr$creen1Trj prograrnrne the unl5[tyof cArntrK1d in partnershipwith Le wwolg ttr¥Ju5and50f Fwle eachyear. Th Teachiro H09it5 TnsL tke£CA)Ok Yorkshi prograrnme presents researcherswith an optKKtunrty lfjdneyScreerrirvJTrial Mll 1wti9atet feasibilityof toalso scen peop for drEYcancerdUring the k)rK31UII kklry cBrrnsueenirgclinical tri. same appoirrtmerrt. a(kJing just Ioto 15 secoTrJsto the lewh of a SCAn while providir#J a weath of imFQrtantdats for research into the•detectKJn "l am parb"cularty interested in the concepts of earty detection and screern'ng for kidney cance Ptofe55orGrSteart 18 yorkshireconcorr¢sear¢h.org.uk
Our ke achievemen Trialling home self-testing for early signs of bladder cancer Bladder cancer impacts the lives of hundreds of people and Yorkshire has some of the lowest survival rates from bladder cancer in England. Blood in urine is a common Symptom of bladder cancer but is not always visible. Testing for non- visible blood in urine could be a way to detect bladder cancer early. Yorkshlre Canr Research is fijrdiro a£l.5M tri that aYn5to detect bl¥Jder Caer earfy through h 7hls CoUldp the way for a seK.testing of urine. Led by prOf0rjW Cattoof simple and easy way to test for the Unverytyof Sheffield aFKI Profe550r Peter&en of KSngs ColWe London, the YORKSURe'trk31 VAII signs of bladder cancer at home involve 6LK)O men and women acrc6sYorkShi. and stands to save many lives" trial will assess the pJ5siknlttyof an eaty(tection programme for bladder caer. Ifthe stY rEtse promislng- eo. If peoF4e fiTrJ it aptable toself- test and weare able todetect bladdercatKers at an eartierstage- there vthll be a Larger stty inthe future to testthis in rTh)re people. FOfesgxJ&)catt0. unNer%tyCrfeffidd.
Improving cancer treatment in Yorkshire and beyond The work funded by Yorkshire Cancer Research direcdy benefits people here irL.. Yorkshire. The more people in Yorkshire that are involved in clinical research trials, the more our regional hospitals benefit and the more able we are to attract top cancer expert5 to our region. Beyond this, medical breakthroughs and new research discoveries resulting from our work are helping people with cancer across the country and the world.
Our ke achievemen Exercise - the next frontier in cancer treatment There is growing research evidence that exercise before, during and after cancer treatment can improve the effectiveness of other treatments (such as surgery and chemotherapy). improve long term survival. and lower the chance of cancer coming back. In direct contrast to the old adage -rest up" cancer patients are now encouraged to be active by following a personalised cancer exercise rehabilitation programme. funded byYork5hire CarT Research. Led Lry Profes4K Rob Copeland at sle1d Hallam UnNsity'S WdlLwng Research Centre. the £19 millK•) pr(wmme wlloffer peOe with canr cess to lrftrcharging cancerexercise rehabilitation befoT4 durirmj after theirttrnent Cancer eXereSPe0altsts. dietittsgns ar¥J pc15t5 work vKth iThJwiJLo1 pat*ntstodevelop indwidualised 1ehabfjrt3tn prL¥Jrarrwne5SJit8J tothe needs of iTrlwidual. The programrre. in partnershipwith ffiebj T&ithiryJ HosFitslsTtusL On futy running 11 receI¥Ear[x$ l(KIO referrals exh year 11 contribJtetoth2gk&al research into thevital role of exercEe inthe treatment Of(8. e want to he inWrO the %Y we supportpeople with cancer to prepare for, and recover frory their treatment. Being more physically active following a canr diagnosls associated with a lower risk of likellhood of recovery." Ftofessor Robert Copel&hJ. Directorofthe Advznced WellteiThJ Re5earth Centre Read more here 21
Funding world-renowned researchers to continue to improve bowel cancer treatment Every year in Yorkshire. 3500 people are diagnosed with bowel cancer and nearly 1300 people sadlylose their lives as a consequence of bowel cancer. Patients are usually treated with surgery and then may go on to have chemotherapy following surgery. For some people. however. the impact of surgery means they are too weak to be given chemotherapy. An internatlonal study inw)fviro IOCW) patients four that givlng six weeks of chemotl*rapy before an operation w35 safe for patients and led more frequentlyyear on year to fewer serious complications following surgery. The chemotherapy shrank the tunUr. often maklng surgery less complex. and already account ft)r one in 14 cancer deaths worldwide. The research collaboration involves partners from three continents has the potential to redu death and Iwm from colon Vvith funding from Yorkshire Cancer Research, the research team - which includes Dr Jenny Seligman from the Unlvefslty of Leeds arvj Professor Dion Morton from the University of BirmiDgham- will now explore thi5 approach with a wider gTOUP of patient5. Thi5 w511 test rf the approach works in older. frailer patients. While further study will investigate whether More extensNe chemotherapy can further improve benefits and 5urvNal in patients who can tolerate rnore intensive treatment. This widtrreaching research prog¥amme stands to benefit tuSandS of patients diagnosed with bowel cancer each year arKI help save many live5. theUnTrRrsFtyof &rrrrir¥Jham. Read more here 22 yorkshlrecctncerrÉsearch.or9.uk
Our ke achievemen Improving radiotherapy for people with prostate cancer Radiotherapy remains an important part of cancer treatment for many people. Radiotherapy for prostate cancer is usually given in three to five treatment visits and only targets the area directly affected by the cancer. However. by treating a wider area of the pelvis with radiotherapy, the treatment may be better at stopping the cancer from spreading and from coming back. This alternative method is usually given in 20 treatment visits. Yorkshire Cancer Research is fvndiry a £l.I million clinical trial, led ty Dr Ann Henry at the Unlverslty of LEEd5. The research will inve5tl9ate whether thi5 alternative method of raJSotherapy can be delivered in 5 treatment visits (rather than 20) witlK*Ut increasing side effect5. -men in Yorkslure are more likely to be thagnosed with prostate cancer at a late stage when the often more difficult to treat This means there is a hwher nsk of the cancer comi'ng back cffter treatment. Our new dinKal trial wiu test whether trecth'ng a wider area of the pelvis with mcbotherapy works better and whether offering thi's treatment in five w'sits ccin be introduced as Rwd more here Or Ann Henry. Associate Profes9)rln ntal0r01L atthe UnNerstyof Leed5
Putting patients and supporters at the heart of our work Yorkshire is a large and dNerse region and is home to many different ethnic groups. For many and varied reasons. some ethnic groups are less engaged with the NHS than others, meaning they may be at higher risk of a late-stage cancer diagnosis. One example is that cancer screening rates among the South Asian community in Yorkshire are particularly low. A newpartnership betsveentheurwewof Bradford and Yorksh1carer ResewchwiThexF4rxe the re&ons for low carKersueeniry participation arrKJngthek)Lrth Asian POFxJL4tin and wdl work wth kxal communrttO wt inptr measures to Intreasescreenlng tstes. The E44lk PYLyamme will LE led ty Dr MelarueCoLyeraThl Profe Marcus Rattrayfrorn the Lknnfer5ityof Bradfryd whospeck?lise In wOrl¥j in partwshlpwtth cornmunities to supKKxt peOet0? better th and access to hedthservice5. tt aims to intrcMJu convers3tions ab0trtcarr into efyayfan rrfe. not anlysupwbng those directty irv0h. but a150 sUprtIng futUTe g2nerdtionsto attend carrer "As a Muslim Paknstani woman XTeening thr(MJghrAJtthe%r I Imng in Bmdford it is concenung that Mustim South Asic women Imng in Bradford are considerably le55 likely to have cenfical breast and bowel Read more here tlwusands of people are missing out on these important tests wknch can both prevent cancer and find it earty. when iys usually eaer to treaL" Hafima k4bal. Re5earth2r aiBr3df<xd Irstitutefor Heath Research 24 yorkshirecancerros¢orclLof9.uk
Our ke achlevemen New Sheffield Pioneers Research fund Tharlstothe legaLyof Lynp3r2a-a drLwJoJr dH[tyhe1Fedtoftthat cwariary fdtCPk2n ar¥J peritoneal rz• uty0f Tr45wiII wJkaf1W1lh the un51S rar[Thl1 kunch ty inriialtyoffthJ upto£8rriIli in rrth fultOhPsawe inyorkth 25
1,11 IritT-: New Ripon shop opens thanks to our deth'cated volunteers Read more here 26 yorkshirEcan¢erre5earch.org.uk
Our ke achievemen United by the cause - a premier league partnership 11 faMilr W{thYkSre CAncw Rwrch OrthlOfLsw thx6ingtO SUPFX)rt a carThchwtty. Oxaim thankStoTSupFNjrteI& Thi5 yearwe have CLyrIt0 partnerwith Lw15 UThied F(thii al. telrujfr(yntt 2xercisewtth (NjrchallervJTrCanpa hRIdtrNjte to Unrted far6 livirowrth cancer bygMrwJ themthe team5 at &land Ro> Stepping out for Yorkshire with the Tour de Walkshire rwleto W thedurirrfJ of May tytaking on a W51(1.mCtst ICKK) signed PFVCal aThl.t(xJether. £150kto fund lrf&sarir¥J TrCl F¥b0FA4ntscCJ1d thctse towall N.t15#KreobleCcffinINtywe unit1 by the cau carr YkShe. eXerC1r4j theyyKvp a&0 hdping to rt4<ofcanTrr. 27
General Financial Review and Principal Sources of Funding Yorkshire Cancer esearch.
Financial Revlew Funding research that saves lives in Yorkshire The results for the year are set out in the Statement of Financial Activities. The financial statements have been prepared in accordance with the accounting policies set out in Note I to the financial statements and comply with the Charity's Article5 of Association. the Charitie5 Act 2011. the Companies Act 2006 and Reporting by Charities. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective January 2019). We are glad to report that we have been able to provide £9.9 million of charitable expenditure. Our fundraising iome was £5.9 million1£4.2rn 20121) and we saw a rise in our total Royalty Income to E19.Im1£15.3m 201211. With careful 5teward5hip of the money entrusted to the charity, we saw a rise in our investment realised and unrealised gains of £1.8m W5.2m 20121) Future designations representing research awards approved by the Trustees which are not yet payalAe have not been included as Ilabilities. An appropriate amwnt of unrestricted fund5 has been designated to cover these and future award5 a5 S5¥n in note 16. Designatlons for fijture awards totalled E52rn at 31 March 2022. an InCaSe of £4.Imfrom the prior year total of £47.9m. In 21)05. researchers at Sheffield University. n(led by Yorkshire Cancer Research. successfully demonstrated how PARP inhibitors COL¢ld be used a5 a tailored cancer treatmerbt. The discovery was patent-protected and linse to KUDOS. pharMalrtlCal company later acquired by A5traZeneca. who coritinued the ¢Jevelopment process. Following dinical trials. drug5, including Lyrwarza. Zejula and Talzenna. have become tailored treatments for cancer patients with certain hereditary cancers. Yorkshire Cancer £5.9 million fundmising income 29
Research has set uptwo fuThJsfor the e0f the (ESGI factors alotWJ-SHJe tradltlonal finandal University of Sheffield. made pw)ssible folk)w"ThJ the metits. success of the discovery made at the UnNersty with ndiry from the tharity. and which urKlerpir6 the drug5. The fuNls will toe an dementofthe th8rity's revenue ¥ecefved from its shareof the unIveIty'S royalties derived ftom sales of dnjgs to 9JPPOrt canr research across univew%tyfor at least the next decade. They are refeed to beknv a5the Yorkshire Cancer Researth Sheffield OneerS Fund aThJ the Yorkshlre Canw Re5earth More Life tr) Lp Fund. Environmental. Social and Govemance {ESGI criterka are a set of stsndard5 trj a55esS 3 company'5 OperatiOr that investors. such as charities, consider when reviewing their Investments.. virthment Criterkcc)swJerh 8 COI)W3ry Sooaltstieiia Examine it rnare$ reLatShip withemp4Lyees.gJFWRr% oJ51(¥ners dt ComtrnjneS r( operates. The net rrLwernent in fundsfoi yw was a Surplus of £1Sm which whenaddal to thefurKÈ brought forward rewlts in furhy bHLArKes to ca forward of £84.Im. These totsl funds are split between general fund5 of £11.7m.dvgnated funds of £52m as noted abcNe and restricted fu5 of £20.4m. As stated in previou5 rep(rts. fuThYitwJ of research doe5 not neSarilyfCI1Qrt pattemof Trustees review investment performarKe Income which the Charity reCeiC to year. against appropriate benchmarks. At the year er¥J the perforrnance of the portrolio as a whcAe wa5 behind the agreed o¥erall benchmark of CA+3%. The Tru5tee5 also employ the services of an extemal Iestment c¢)nsultant on an annual basis to review the perf(xmance of the investment rnanagefs and report back to the Board. G•edE$ith a tompany's k•Jetthip. ghts. Our Irwe5tment Mana3ers are expected to take count of ESG Is$L5 In their Investment ana and decision-making pr£55*5. Investment Policy and Portfolio The rnain investment portfolio of the Charrfcy has been managed by Quilter che0t sin March 2013 and in December 2019, a new portfolio wa5 established. managed ty Smith & Williamscm (now Evelyn Partner51. Yorkshire Cancer Research ha5 a detailed Investment policy which goverrs how our fvnds aTe inve5tEd. The arity adopts a W[ent and well diversified investment strategy. airned at balancing potential turnS with appropriate levels of risk. The portfolio Is invested in a raThJe of a55ets in line with pre-agreed a55et allocatr. At 31 March 2022, the marketvalue of the investment portfolio was £35.Im and included an Ltnrealised gain of £2.2m. The urbrealised gain arose from the recovery to global st(Kk markets fcllob¥irrfJ the impactof the Covid-19 pandemic In arth 2020. Du¥iTr3 the year. investment portfolio irKome was £828k, and realised 105ses were £675k. The current dimate creates a tough fuThYraising environment arml this is likelyto continue for the year ahead. However, we are cornmitted to the research we are alreadyfunding and to maknng further awards this year. CanceT re5ea¥ch is more vttal than ever and that 15 why durirrtJ 2020121. we announced £11.7 million in nert research funding fof fLrtuTe year5. Irbcome geratIOn is a challenge we can and must meet, in order to continue to save lives in Yofkshire. t#)th no%y aThJ in the years As stewards of Yorkshire Cancer Research's capitsl. it is important that our investment managers are signatorie5 of the UN sUPPOrtEd Principles for Responslble Investment (UN PRI) and that t have incorpor3ted the six principles on which it is based into their investment process. In particular. It Is Important that each investment made con5ide15 Environmental. Sodal and G0vemae 30 y0rkshlrecancerre5earck
Flnanclal Revlew Organisational structure heralded the allival of other 5imilartypes of canr dwug5. providing Patnts wtth vital ditional treatmentoption5. The charity is govemed by Articles of A55Clat)n which Set out the charity's objects. its powers its constitution. The charity is also governed by its Board of Trustees. the Trustees of the chartty and the Direct5 ofthe charitable company. The Trustees have legal responsbilttyfor the strategi irection and effective govemance of the charity and for enring that the charity is focused on achieving its objects, continues to be finarKlally sound and uses Its resources to delwei maximum benefit. The Boa of TnJ5tees met seven times durirrtj the year vla Microsoft Teams. £9.9 million in research funding The Chaimian Of charty %%Y)S dosety with Chief Exec(rtfveto ensure that Board dectsK>n5 arè acted upon the tharity 15 managed effeclivety: this includes develoFMng and •Jreeing the strateolc directionof thethJlty approval ty the P4)ard. Grant Making Policy Research is atthe heart of all we do. Each research award that is funded must meet the charity s strategic aims to prevent. diagnose and treat cancer for pecple in Yorkshire. The quality and strategic fit of apiCatiOnS is assessed in on competitK)n with the help of th2 Research Advisory Panel. The a55e55rnent proce55 is audited and approved by the AsCIatIOn of Medical Research Charities. Final apprcwal of fundirvj Is reserved to the Board. Public benefit Our Trustees confsm) that they have referred to the Charity Cornmi5sion's gerTal guidance on pttblic benefit when reviewiThJ our primary activities and objectives aThJ in planning our future strategy and direction. FblIC benefit is at the heart of what we do a5 a charity and this is demonstrated in the ¢bfe-giving medical breakthrough made through research funded byyorkshire Cancer Re5eaTch. The roydltie5 we receivefrorn the drugs developed as a result of these breakthroughs go straight back into funding further resewchthat will chaNJe lives in the fvture. Award5 are maje underthe terms of a tiinding written framework including fom)al Award Conditions ar¥J Policies fot Awards. Applicant5 are required to adheTe to best practice standards of research governance and ethks. Other fomial terms deal with the handling of intellectual woperty Ptoduced by the rEsearch and its potential eXoitation. to ersure the charity's interests are proterted and thaL where appropriate. a retum on publidy donated furhds is In 2014. Yorkshire Cancer Research funded a first. Lynparza. a dnjg developed In Sheffield. became the world's first licenced PARP inhibitor drug. successfully extending the lives of w0nn with a wtsin type of advanced ovarian Canr. Since its launc the drug has a150 been liceed for Use for Some breast canr5, pancreatic cancers prostate Canr$ and trials are on- going to See if it could be effectwe against several other cancers too. In aldition. by shDwiThJ that PARP inhibitots can be made to woik. Lynparza has Regular meetiros are held during the conduct of the Award wlth Award Holder5 to measure progress against agreed key performance indicators and to assess progress against Award impact. 31
Fundraising Standards be effectNe duriry the pandemic. We will continue to evofve OUT risk management as the ongoing effects of the pandemic continue At YoTkshire Cancer Research. we work hard to achieve best practice in fundrai5iryJ. We want our supporters, donors and anyone who comes in contact wtth us to feel they have been tseated with ¥e5peci and considerntion. We subscribe to a) Managlny strateglc charye the Fundraising Regulator and Code of Fundraisirrfj tt 15 of paramLmt irnportance that charitie5 are Practice and activety follow their guidance in clear aljout their purpose atKI stratwi aThJ how parallel with that recornmended ty the Charity theywll manage strateg¢c chaThJe. Without thls Commlsslon for England and Wales. Our lrtome clarity. the could be a lack of adequate planning Geneiatlon Commlttee focuses specificalty on arKI inefficient Use of resources arKI. ultimately. fundraising activty and the Oirector reS)nSIble a failure to deliver the required public benefit. for Yorkshire Cancer Research's fundraising ten.yEar plan agree¢J bythe Board In 2015, activity reports to this Committee. We also take and refshed from Septembei 2018. is belng caTe to monitor and address changes in relevant ree. particularly in light of the pandemic and regulation that rnay not be 5pectfic to charities its effect on Caer patients in the region and the such as the GDPR legislation. development and progre4 of the implementatlon plan Is being carefulty monttored. This review proce55 may result in further strategic changes. b) Dernonstratlng publk ben•fft The g)al of YoA(shire Carte¥ Research is to Meeting and eXainIng our WO to pK)tential achieve 2000 fewer cancer deaths each year in donor5 is irnportarrt in funding our workto Yorkshire by 2025. The public benefit we seek prevent. diagnose and treat cancer across to deliver is. theore. thè effectiveness of the Yorkshire. To do thhs, we work in partnership with a research and 5ervice5 that are fUled to prevenL specialist, market-leading fundraislTYJ organi5atiorL diagnose and treat cancer across yoThlre. We require them to cOrnP with fundraising regulation and to display the hvjhest levels of professionalism when talking with potential supporters. Mystery Shoppers help u5 evaluate the degree to which they achieve this and we will work in collaboration with them rfwe recelve any complaints. Response to risk Working with Third Party Fundraisers This year. we contin developiThJ our impact analysis rTKtel. which ha5 refined our undeTStanding of hrm to reach our gDal. Our priority areas have been selected on the basis of delfverltvJ this significant public benefit and indude clinical tria15. smokince5sation. cancer rehabilitation and earfy diagtK6iS. Risk Management The Research and Semces Team reprirts annualty on the irnpact of the charty arxl provide5 regular The Board and Executi¥e Team regularly reviews upJate5 on the prowof key strategic area5 and the major risks to V4hich Yorkshire Cancer Research the impact KPIs_ Is exposed so that as a charity. we can be satisfied that effective and adequate risk management c) Cornpliance and regulatlon and internal control systems are in pla. The Yorkshire caer Res&arch continues to grow uncertainties include risks to IrKome. the ability in ordertofund at least £IOm of Tesearch and to fund long-term expenditure and risks to patient servi05 everyyear until 2025. To comply reputatton. The framework is designed to manage with regulation and to mltsgate risl the stfucture, the ri5k5 to our strategic aim5 arKI has proved to organisation. systems arvj contr(A5 of the charity are regularty rewewed. enwres that the 32 yorkshirecanc•rr•searclLorg.uk
Flnancial Review starKlard5 of management and control are always maintsined at the most approprSate level for a tharity of our slle and Importance. Safeguarding Members of the Public We continue to make signrficant progre55 to professionaltse the charity. meeting new demaNIs ft)r improvements in regulations relating to tsx. data Protection. donor and volunteer stewardship. health and safety, risk management and a greater emphasls on good employmerrt practices ar stfengthening our govemance framework We are espeualty careful when engaglng vulnerable pe(*)le and those affected by cantèr. charity has reliewed how w recwuit and appoirrt ernoyeeS. To supplement the usual qualrfication arKI reference checks. we request a utminal record (hed( as part of our reuuitment proce For certain roles the chKk can a150 Include inforMan held on the DB5 children'5 and adults. bawred lists. tojether with any information held ty prAice forces. that 15 iea50rk3bly considered to be rdevant tothe applied post. As we have noted through this reporL the environment for our research and services has been impacted by CcwSd-19. OinScal trials regulation. approva15 for new drugs or new treatrnent pathways along with the availabilty ( cutting-edge equipment and appioprsately skllled personnel have all affected the abllity of the charity to delNer oui furKled projramrnes. Subsidiaries Wo(xJs Bacon Factory rnIted. a cornpany registereil in EnglaThl and Wales (Company number 003479041. is a Whol-0ned subsidiary of Yorkshire Can1 Research atyj wa5 left to the charity as part of a legacy. The principal activity of the company is the letting of tts properties. There wa5 no trade in theyear and Wocmts Bacon Factory mited was on 6 July 2021. Reserves policy The charity ha5 revtewed its Reserves Poliryand agreed to continue to invest in research over and above net income levels by drawing down from tts reserve5. The charity has decided to have general resetves reflect the expected level of opeiational expenditure and designated fursds represent Research Awards approved but not yet incurred as ell as anticipated fUre Research Awards. Y.C.R. PromotK)ns mIted {Company number 2618142) and Y.CR_ Soentific Developments mited (comp t)Jmber 4194001). cornpanies registered in England arvj Wales and whdly-owned byyorkshtre cArT Researth. were dormant during the year_ The policy is for the level of general reserves to reflect 18 months of future anticipated operatiry cost5 established at £9.9m. General reserves at 31 March 2022 were £11.4 mill¥)n and are therefore In Ilne wlth the policy. Structure and governance We said gcodtye tocatherine Rtjstomji who served a total of 6 years antj Chrls Slater. who had served 3 years as Trustees and have seen the Charitythrougha rIOd ofenormous thang& Complaints. compliments and feedback are an Our artfelt thanks go to CatherSne and Chrls imrtant SWTce of information on our ¥k for unsbyerving dedscation to the Charity with our impacts on our supp)rters arKI members of the best Wi5he5 for the future. We are delighted to public. providing us with insight and lessonsfor welcome Sam Jenrer and Matt Johnson as new future artwity. In the year to 31 March 2022. one Trustee5. who bjth joined the Board in June 2022. person rnade a complaint to the charitythroughour Their experien will be a valuable addition to the complaints process. The charity responded aThY the Board. complaint was reS0ed. We takeall feedbackvery seriously and act upon tt wherever possible. Complaints 33
Trustee recruitment. appointment. induction and training They are ojrrenty. The recruitment pre$S for Trustees 15 cariie(l oui by the Remuneration and Nominations Committee and new Trustees are appointed by the Board All Trustees give freely of their tlme and receNed rK) remuneration in the year. Details of Trustee expenses and relevant third PartYtraract1OTrS are disclosed in note 7 to the financial statements. Trustees ale required to disclose and reyister any relevant Interests arxl the charity uses appropriate protedure5 to a55e55 and deterrnl the proper course of action where a conflict of intwests arlses or may be percelved to arise. New Trustees are selected to fill arhy specific skills gap5 identified. Prospective TIu5tee5 are given a comprehensive overview of the charity's actiwties so that they fLtlly understsnd the contribution they are expected to rnake before they commit to becoming a Trustee. They are gwen guittan on the structure and governan of the Charity. meet with the Chief Executive and are appointed to a Board Committee. New Trustees reNe an inductlon pack of key documents. Induding contract of commitment, ahead of their first meeting and are required to work through these documents with the Cornpany Secretary. Any Immediate trainlng needs are Identified and incorporated within our Trustee development programme. Remuneration Policy charity has a responsibility to ensure remuneration Is appropriate and affordable an(5 jU5ttfiable use of charitable fund& The objectives of our Rernuneration Policy are t ' rward My)baSe thefrskllls. perfomwnce. contritrArtfiDn cotrrfnltmenttothe char5ty Trustee Delegation The Trustee5 are perrnitted to delegate their pryNers to Committees, which repoft regularty to the Board. These Committees may Include Trustee5. member5 of the Directorate and other senior managers, and independent special adviser5 from outside the charity. Each of these Committee5 is non-executive and has no executwe powers other than those granted in their rpective terms of reference approved by the Trustees. enable recwuitmEnL retelltion and mDtivationof Iwjh lie npbje5 in aH areasof activity erFjvEt PrOpETw effecti u5eof our resou5 ythin sensible, affordabtelimits based on the financlal hth thestrateglc thmsofthetharity falr eqtale In setthig and marwglng paylevds soasto [de a rdk8Lle at¥J gJStalnaL4efreQrk comFtywith al relevantiewL4tionsand emplcsyment gtIL e5peciilly in reL4tlon tostatutoryobligatlons. 34 yorkshlre£ancerresearch.ory.uk
Flnancial Revlew malntaln a competltive POSitp)n In theextem emF4oyment market ty ptyr4at or abo then level for conparab posts Snthe ¥Cknntarysect. In preparing these financial staternents. the trustees are requlred t sew su6tstrJexcowtlngpcMes dthen appty them CO$¢enY Remuneration Is revlewed on an anThJal basis and agreed by the Board of Trusiee5. When setting pay levels. the charity gNe5 cortsideration to extemal benchmark ccfflparators. change5 in the n3thal and regional average pay movements, affordability and other Internal and extwnal pressures Indj0j recrultment and retention. the rrnthoI5and ryincple5 inthe Charitle5 esUwAte5that are rea50n8ble and prudent prepare therInclastateMents ort the 90irtg concem basts Is Inar4)rq)rfateto pregjme that the ch¥ttatle conwyv4111 contlnue Inoperauon. Management The Tnjstees have delegate(I responslbS11ty for the day-to-day management of the charity to the Chief Execuibve who has the foilowirg respotlb1llties'. 4 5trategic- towovyje inwt and d)8lktye tothe devebpment ofthe chariiy51ory.term traTratJnof that Strategy 1nto0petatK Flarts aJwatarytrnethefnaThial FLrtthOfthe ¢tsitthComtkywg0Up enabletht0 CLYnwitKffi.TWareaLore5Pl6lefL leadership and delivery-to den¥erthe 5trateand operational plans and managethe chariiy thin the ddegated authoritiesand accountabA1tyframe4xkS down tythe Auditors Board sUP-t0 Implement Bo3rddeosw)rts and ertsure they receive the Information èlictthty asa&litDr5rffi IS March 2022 fdky•r0afomteTrYerprC(e$S&jIT* apwovaL Statement of the Board of Trustees. Responsibilities The trustees. who are a150 director5 of Yorkshire Cancer Research for the purpose of company law. are responsible for preparing the tru5tees' report and the financlal statements In accordan with applicable law and United Kingdom Accounti Standards Iunited Kingdom Generally Accepted Accounting Practice). Company Law requires the trustees to prepare financial statements for each financial year which gwe a true and fair view of the state of affairs of the charitable company and the and of the IncomiThJ resources and application of resources Including the income an(5 expenditure. of the charitsble group for thatyear. 35
Independent Auditors Report Yorkshire Cancer Reseaich 36 yorksh1recancerreseu1L0ry.k
Independent Auditort Report Independent auditor's report to the members of Yorkshire Cancer Research Opinion Conclusions relating to going concern h85 bEen appld in thsreF#Yt ge a twe and falrvknof the stste chafftab compan$ affairs asat 31 M¥ch 2022 8ThJol its IrKomlng resourcesand applatson of rexr[e Indudiny its IncoN and expentfftwe.fE¥rthe yearthen ervJe4' Other Information . have been properfyprepared in (1)rdKerth Unft•J a¥thtcrt reFt¥tthErwrL ThEbU5tseI5PL¥GIEfL¥thP have been prerAred [r•accordanih the requlrements of the CoryarOesAci 2CIJ6. Basis for opinion requirementsthatare relWarttrJtxrafrtofrIWJ staterrts intheUKincknfirotheFRCsEthKaStaTh P¥ba*sLUr0PXnILyK
Opinions on other matters prescribed by the Companies Act 2006 the inforrnation given inthe Tn25, Repxt.whKh Indude5the Direcior5' ReFy)rt ¥nJ theStrategK Report ¢oJrtitvJurknthetnJ5tee5alhu rrtendto&yidethe prepared for the wrpD5es of axNparry law. foTthe rinancial yearfcr%¥hiththe firArKi 5taternents are prepared iscon5i5tent yth the financlal statemen and the Director5. Report ard thestrategic Re[ InckKled Svtihin theTrusiees' Report ha% been prepired accardance thaprab legd reqreMent& Auditor s responsibilities for the audit of the financial statements Matters on which we are required to report by exception Incbded wrthintrTnth'F&rKrt The extent to which the audit was considered capable of detecting irregularities. including fraud adequate accountiThJreLOrdshe noi tr•nkepL or return5 adeqvatefor ourau(fit not been recefved frun branche5 ntrtv1tsrf or the financial statementsarÈ Inagreeffntwilh the accountlng records and roknrn& or bylaw are not madtr. or ' we have not re£eNed all the Irrfornkn arKI £%FAanatKthswereqwrefgrLWTau Responsibilities of trustees AseWir& mrefiAtyIn Statert0fTnStees. ¢f£oryanylawl¥e resFWJrtsbtheF¥KLth 38 yorkshlrecancerr*search.ory.uk
Independent Audltorfs Report Use of our report (StirtrwiahlfurK)othyY.TQlfr*fUjestextent 20110122
Consolidated Financial Statements Yorkshire Cancer .Resea(cli 40 yorkshlrecortcerreséortlLorg.uk
Consolidated Financial ststements FINANCIAL STATEMENTS Charity Statement of Financial Activities (Incorporating an Income and Expenditure Account) for the year ended 31 March 2022 Totsi TotAI L75i9)2 ZJ61944 1,386J98 17S1653 1826.392 749249 15.294.430 Total IrKomlng resowces IS.7S06 10.080.695 25AX.S 20.288.SOS ExwditurÈon 1709.C69 ILZIJIZ EwditurÈonthattsNeaÈtr 2A<L45 9.945JO8 IOJW05 Total re50urce5 expended 10.199.595 2.454.2 12.654.177 13.007.717 S,18B,230 IltInc0rn* 7.568.181 IS,014.867 12,+169A19 NetrncvemEntslnf 78.1 IS.014.8S7 12.469.419 770 54570 - 693&310 56.56&92L Fund balanSCErrfed lorward 31MarchZOZ2 63th.356 £JjA2250 84PSk.207 69.036.340 41
FINANCIAL STATEMENTS Charity Balance Sheet as at 31 March 2022 Company number: 01919823 20 Tangitrde 22&5 17&900 IrNe5tmEnts 57.788535 4008 7nJ78 550.057 58.791432 41.134.957 4WM814 4406359 34.550 Cashat bankand InhaTrJ 19,gJl9SS Z8,WgAS2 28.737,329 34,515.811 4785541 (6,614.428) 25.258.775 2?.9.983 Total ayJet5Ie55currentll4e5 84.QM.ZQ7 69JTr35.340 FuTrJ er frJThJ5 IL66&1U 8237.452 [snatedMs 5LW46 47.944.318 IU54,570 Total tunds 6451.Z0? 69.036.340 Graham BeTrlle- Chalm 42 yorkshlrocancerr£5earchnrg.uk
Consolidated Financial ststements FINANCIAL STATEMENTS Charity Cash Flow Statement as at 31 March 2022 l?J44JJ2 Ktmtles Inve5trnent income (4,7S8,648) JrchèseoftanglbkfMedats (a01 JOW86 )6.1517 Cknlevaluèkn U6.9y.n8) Ch4ry•ln¢¥h•ndcAth wWrrtStnll* W•FX>rtingperfod CashaThl IU.a17A87) 5.909J65 2&JOgA52 U2(M) Cash cashe4UNalentsatX Ma¥ch2022 28.109.452 aw9.452 I8.2A8n ,wi,g Total 28.109A52 (8,207.4871 19,901,965
FINANCIAL STATEMENTS Notes to the financial statements Accountlng polldes Fund 4Kcountlng Charlty Informatlon re5tredaS8rttyth p1paI pkcE 01bJne$SI$j•jJtssrth1bJ. 7&ThEPatkCtsrt Hawat4NorthYrrfksfvir¥, Ear, DPeratnSartSetojI InTStee5ty BaslsotproparatloTh PractSc•appliclit0cIi05WtprirOknfino51•t4n Inar¢tydancewtthlfv Fknanc Repu1c0f freland(FR5 I)lettEr1Thl uY2019j-(cl1t5 Incombng re50urce5 UKandRewtrAlcOflrer1FRSIlj2)•ltrcrykkZ StLY11 w5tuftr5tbnvUÈUes$lthl5t51ètsllhe Epared kn PoLrfStedkngastNsK%voJttW0fiJwwIWy DonatSons arnl grnnts CarKer Rese¥th)tw beend4sokd¢knrfrytreyw.ltsre Yorkshlre Cancer Research Status YarksNrÈ CanrerRi5Earth Royalties 1kn5tEdto£l PErrneThkn. Golnytoncern ThErnte¢ShWE WEe¢d forÈcasiXiivkyforaia5t 12Montr&frAkiwhwarvth f£1 5tatemonts. In thE1tl ie5E[VElwptstTrwvVed IniÈrEsiand dlvlderK15 theChaiStyhb5ade4uate rp(e510rOmnknlYrknnf0rlhe Resewth•sB tEteredOwty15rrf>tliBNetOtBtiOThth of èccounbry In yparln9thOfinanc1SLlt0mont ThÈTIu51eosO) ntnSIderere1VbenytErItiIn[EriuknUbtthE*l[1S abll5tytocoThtel5arQc<Srrrt 44 yorkshlrecancerresearch.org.uk
Consolidated Financial ststements Aeseerch projects Kc0untEdfora5inLurd1jrirytrÉ•r.WhÉrgrnts•r Aesources expet)ded stock Contrlbutlons to PenOnrS LV5tsttire[tty•ttribJtaLqetotrKlrlity.Y1hpC051s£arrtb T•ttglbl¢ flx•¢ •sxts •) depr¢l•tlon Tar¥JiblÈ IAdassets arÈstatÈdat<tyt.ie55¢JEPEtsknL OpplKiagioniswldOnt0 fixodajsetsatrates <)peratlrvJ leists FRdedUSE FIMncl81 Irtstrurntnts lo> Lthsewl rtllW(VIy IAolorvElide5 Crltlol accounlSngludyÈrntnts AX asset Inve5twTrts ¢Jet¥thlth0aKjTts0155EtsaJ1b1rt5b expenthure Imiestme#ts- quoted IrwE5tmpnt5are5tstedBt 1fthetEhybPEnwP1KalOt50ftsrOJTrtIn e*oth¥e rrAthiierFWtyu•Jit fdtyrwahdewtyxtdiecvab1lty. ThEr• 45
(Note5 contlnuqd) Accountlr¥J pollde5 (cryrtlnued) bEmEt. In5LVtrKEE.tWyIsrbEEnrQTrd1 Determlnlng re51dual valuesand useful econ0nC Ilves yeaend[1dedtNndbtr.0UÉto1he roiweots(wrf of property. plarrt.andequlprn8nt the 1egadesfKEE.thEL5 jL¥wnentapprtDth&Vl K•y sources of estim•llon uncertalnty theperi¢d knwl4¢htresinie$fe%id.if Iheth5bJnotlKtsrx thBtperiDd,orlntrperbJ¢theIekn1¥ffidj1lTrm1ts riEtennlnlngthe Valuaon01 legacydebior5 ofe5t1mati0n1KtaM.thILh51r0fictrolury tEWWEdtobeytythRE5trtCtll ree¥hEOf1e kgary. Incomefrom donatklrffj and grnnts T¢ 9E4I314 gf4n4 995 95267 Reta 33i74S antsrecelved 41QfM2 105 $475Z Othe1&maUr L752.902 4UO.042 2.161944 1,386,198 Income from le9ades Total ToiAI IndIdu gw9-le5 I?63 26392 3.7S]S] 17¥A.653 1826.292 46 yorkshire¢oncerresearch.org.uk
Consolidated Financial ststements IbW•Stment 5ncom• t6nd$a1terestC4TrIrA%fffl ?8186 Eyndlturè on fundraTs]rwJ Totsi zo IWwity4rvJfurfraisroJ 539. 539,701 IJ34.032 U34M32 LIYJ2,131 19U31 6516 15,767 47,736 47,736 751>33 75P33 4S 461 61M2 97.552 98.J92 2337 I706.7a2 I709.rA9 3.735 1117.577 2.12L312 47
(NotthIft1ftTh)Ie 16.
£2•216505theBJlWstrQefJdésI5*ed1Eta1rYjtQl&
48 yorkshire¢an¢erre5Earch.org.uk
Consolidated Financial ststements Charliable acllvlUe5 (contlwed) 30 BtaifrydCCG (27 41688 Vniwetytyofl L¥l.938 774.354 1,281,767 VniwetgtyofLEsts 363J84 146J9,$00 iÈÉdgGtyCINwl 4%293 49ffl2 utweTrtyCoegp LO0 29.1 I,SS7,517 UnfversiiyofSheffi 3,545 3.759 Sheffiekl HallamUnhrty 43NSS awteDistrfCtFtyJTrJaOnTnl (4Z171 44JOS unrty0lOl S26350 7W.g Ilorthjmbrfa Unhwty 8S9 42.211 9Jbtotsi 45041 L4W335 Z6.974.395 UDNersityofSheffield EThSMrom Fundret 3&1%9 5QD5n SupwtC051515 page50) 40.512 Totsl 5.867.586 s28.240 26.974,395 49
(14•tes 1•) Charltable actmtjes {contFNed) SupportC05ts- charItablaCvlll5 Staff tt IW5.913 I,OZ7,748 wage5aTsaLrls 6P37 37 31 sètskntycasts 44.923 5.195 4.959 L2galaThl prOf5y1S &783 L494.950 172.280 Emplwes To Yo Wagesand salaries I.[ 1.844.175 lscutity£D5ts 3J5355 175N17 )856 114,144 Z.143A36 £YOml - flOO.OOQ £80.(M)l -E90.000 £1001 .f&).e J.QOL .£70M S¢i¥kes.OirectDr ThE tuebe[tsNdMthe(Q5lufEffyeIS Nknn ITan&CotIQnSDttEEXEoJI1v¢tCwwE É45895FU021.£487.5491. bohilfofVorkthlreCaKer RurChrirytr*ar2D2I-£N 50 york5hirecancerresearch.ory.uk
Consolidated Financial ststements NetInrnIng resources forthe&ar are Stat after charyl Totsl Total Al{t Fep5 23,035 54.894 Opeiatirgkoe rent pabJ- 9&712 g. Tanyiblé flxed assets operty fijmkne & OIApri13)21 3XA52 4396n dOrts 249 137.691 31 Z022 eprEclgUryi Oi April 3Q771 0wrgetlwv1Wr 71330 3IMwth2ffj2 78AX Netbookvalue 3L037 2265 at3lMahI0Z? 31 K*arch2ts2k 4.ia 176.900 51
- Flxed asset Irp4estments
Total
artetYat IW12011
7fi595
2&172
ditbr
7J54,ODF
1&05L782
25JQ5.789
23ffi7597
Lp05it3
Q2W16)
I16?j
4.75B
Markelvalue at31 Flarch2022
35.096.158
21.692.3n
SF.7a8.535
Urtrea1d
2A¥J 4.758fj48
Total Aalis
7A45 125S.353 35m6.157 32.752.622 At31 Marth2022nDQIE11n9eXrEedd 5%0fIheofVKfdkn{3l IA¥th 1021no(rfWr¥Jexe•l&JSY4 Trk1rwestmentp¢rtl¢lo*s•JMtsted¢)Jlt¢T ovAL4rtvj É¥etynPwtnw 52 york5hirecancerre5eartlLorg.uk
Con501idated Financial statements 14582 YLR. p>tmUThYt8J-C0sl3I March yLR.knti Ltirited-costat31 March3)22 202 14,784 Iiiwrrtofit5B55ets. bIO51nds8l3I Marth 2022111(3)2l. £7.>J7XThEcEYnpUtstL%orthEYearto3l K4¥th2021 harfty TLrt•l IAwla)ZE 55),057 217,321 311AychlOZI 777.378 knpalrlnwrt 31 March2021 Netbook¥alueat31 I1Ch2O22 777.378 777,378 31 MarthZIFZI SY).OS7 Cl$ Blotethnologyumlted a)21. BgJldOFwrturwtk5PLCwa59Jb5EqupntyiewfflEdOEthOttrNPLc•dyoStthtoV% DfthpLDrthn5tock Exchangeon 14 klryJ)21 AsèresultOltrSthQW1tt wasr5Edn1ht I4¥th21 fin$tfflentsandtr irNtstmtot tsvalued ktthpaThKjUntorpJntyph ar 1142160fthedsNwe¢ép#. Itsw¥wdx1Mtyi4thEdQfb0ykJents 53
(Notest¢>ntrrtuqd) InmIne*lthInlThS Tradedebtars 676?53 4J,261 6%7n L598MY8 5A44AI 4321793 8.8ty)A14 6.406.359 13. Gish at bank and In hawwj Cash atbank and In hand 19.901.965 28.W9A5Z Creditojx amntsfa1lIng duewlthln oneyear 314272 TaXètknftar 49.381 ,140 3j61 (438A 3AW54 6.614A2B 54 yorkshlrecancorresearclLorg.uk
Consolidated Financlal ststements 1% OperatlbVJ Itase commltrnents Charfty IO&YJ5 EMpiringtwotofreJw 195,325 215.773 150.160 i& stst•m•nt of fund5 Totsl Jnd5 Fur ToLh AtiAwP 8231A 4IW.318 I445. s127 21LJA5 69I1W40 3.191W 61Q042 25TrL52L 2041 111654177) Net IJ95A55 L837,5LI UWi.349) dÉsv¥*tsdduritKJthe At 31 mah1o?2 .665.111 Sl.963,246 Z.Z3&769 IOA48MI 5.794.657 s5?23 84.051207 55
(Nots continu•d) 16. Ststementof funds(eontlnued) ofH k%yLir Atiwii 137,315 .921 507,U96 759 Ewuiture (ZJ5UWI 11811651 WJI8) IF7422BI 13MYJ (U8) iow7.n71 Net Irrtstmont SJ8&23) U5.6VJAMI 1624740 .FuThts dÈ5bJn3ted OJrfrrfJthe At 31 Maich 20a ¢237,452 47.941.318 I65+ 1444769 5JJ37.527 2595Xdg ZU.185 696. ItnEcledindp9natedfuds.TshththE¢JW1tySStrtCclTI¢1Spp¥¥tlQryeUa£tits¢tsYealnS. trllgreemwt. th5$fvr bbEWVJu5Edt05waS&wIeswthaw[dtotrUrknVOrleeok TIbtYothslr•cnClr RhSn¢ LifTothFunrtatie5trKtedfvnd5rd&tiryts> Lynparzartyatyshaie iecVEdquarLertyttrrfWtthe Ftr¥ttl*dtQ•WrtreStbPrry irrtestmont atntn 56 york5hirecancorresear<lLorg.uk
Consolidated Financial ststements 17. Analy515 of net assets bet¥tstnfund5 Fur of Tou TWfixÈdasse 226,5ty 226.5J9 3 25,24776 IL66SJII 51.963.246 996.320 2236.769 10.848ml S.794.657 557.023 84,051,2 Tctsl Furh* Fl¥nEE Tart¢xEd<ssets 17Q9 7A95.711 B353 $611QJ 144S,769 SOJ752P 211185 27A)LJ83 8.237AS2 47.944.318 I.565 3.44S.769 5M37517 2,595,089 2IL185 69.036,340
(Notsscontlnu8dJ 18. Reconclllatlon of nèt lrttometo net cash flty#from operntlny artl¥Jtles Net IncOnl¢rthÈrtsrYJpWXj W69A B4320 6ml 12.394A551 3285.228 (D&[P3Se)Anrree wicrvJitor5 13J3S873) Netcash WLwldedbyoperatingattrtle5 71q251 17.444,312 19. Contlngent ets 20. Related partytran5arllr Thetota 4gwatevvlueofdomtlrs1WTTrtsttesI3)125Dl2Ol li1ere5tfxteb(EL0.wOmIt[n2o2O1Oo2e 58 yorkshirecancerre5earclLorg.uk
Consolidated Financial ststements Dot% l386J98 Leqacie5 InStMent Income 707th9 74395 781064 7W16 7fi32.&6 294A32 1i9)8,074 7.nimz 20289, ExPendltweonfwMithJ lll7577 Expendltweonttbaritst4è&tMtE5 S597 SXI26240 10,893,827 7J8SJ64 OJJ75 NetIncts* I7247 737. Tran5fer5bets¥eenfiKAÈ J64 9.113 W62J77 I&0242 lo566 S6.SGS.918 Fund bafancescant4dfoJ%¥ard31 M4rchZD 174525 11854570 69,029,09S 59
Yorkshires independent cancer charity Yorkshire Cancer. ,Research,. REGisfERW CH4RITYNUIA8ER 516B*lEanth Walesl RESSTEREDCOMPAfwNUMBER 823